We have previously reported that prostaglandin F 2␣ (PGF 2␣ ) activates p44/p42 mitogen-activated protein kinase (MAPK) through protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the mechanism of vascular endothelial growth factor (VEGF) synthesis induced by PGF 2␣ and the effect of incadronate on the VEGF synthesis in these cells. PGF 2␣ significantly stimulated the VEGF synthesis in a dose-dependent manner between 1 pM and 10 M. Bone metabolism is mainly regulated by two functional cells, osteoblasts and osteoclasts; the former is responsible for bone formation, and the latter for bone resorption (1). Accumulating evidence indicates that bone-resorptive agents such as parathyroid hormone and 1,25-(OH) 2 vitamin D 3 up-regulate RANKL (receptor activator of nuclear factor B) expression through their specific receptors on osteoblasts, suggesting that osteoblasts play pivotal roles in the regulation of bone resorption (2). The bone remodeling results from the coupling bone resorption by activated osteoclasts with subsequent deposition of new matrix by osteoblasts. During the process, capillary endothelial cells provide the microvasculature, and osteoblasts and osteoprogenitor cells, which proliferate locally and differentiate into osteoblasts, migrate into the resorption lacuna.
Bone metabolism is mainly regulated by two functional cells, osteoblasts and osteoclasts; the former is responsible for bone formation, and the latter for bone resorption (1) . Accumulating evidence indicates that bone-resorptive agents such as parathyroid hormone and 1,25-(OH) 2 vitamin D 3 up-regulate RANKL (receptor activator of nuclear factor B) expression through their specific receptors on osteoblasts, suggesting that osteoblasts play pivotal roles in the regulation of bone resorption (2) . The bone remodeling results from the coupling bone resorption by activated osteoclasts with subsequent deposition of new matrix by osteoblasts. During the process, capillary endothelial cells provide the microvasculature, and osteoblasts and osteoprogenitor cells, which proliferate locally and differentiate into osteoblasts, migrate into the resorption lacuna. Thus, it is currently recognized that the activities of osteoblasts, osteoclasts, and capillary endothelial cells are closely coordinated via humoral factors as well as by direct cell-to-cell contact and that these cells cooperatively regulate bone metabolism (3) .
Vascular endothelial growth factor (VEGF) 1 is a potent angiogenic factor that induces endothelial cell proliferation, angiogenesis, and capillary permeability (4) . It is well recognized that VEGF is produced and secreted from a variety of cell types (4) . It has been reported that inactivation of VEGF causes impaired trabecular bone formation and expansion of the hypertrophic chondrocyte zone in mouse tibial epiphyseal growth plate associated with the complete suppression of vascular invasion (5) . Moreover, evidence is accumulating that osteoblasts produce VEGF and secrete it in response to various humoral factors (4, 6 -9) . We have recently reported that basic fibroblast growth factor and prostaglandin (PG) E 1 stimulate VEGF synthesis through the activation of p44/p42 mitogenactivated protein kinase (MAPK) and p38 MAPK, respectively, in osteoblast-like MC3T3-E1 cells (10, 11) . However, the exact mechanism behind VEGF synthesis in osteoblasts has not yet been fully clarified.
Bisphosphonates, stable analogues of pyrophosphate, have been developed as potent inhibitors of bone resorption and effective tools for the treatment of various metabolic bone diseases associated with increased osteoclastic bone resorption such as Paget's disease, tumoral bone disease, and osteoporosis (12) . Inhibition of osteoclast recruitment, osteoclastic adhesion to bone surface, and osteoclast activity is known to be the main mechanism of the anti-bone-resorptive actions of bisphosphonates (12) . On the other hand, at least some of the effects of bisphosphonates on osteoclast development and function are proposed to be mediated through the actions to osteoblasts (12) . It has been reported that ibandronate and alendronate induce the synthesis of an inhibitor of osteoclastic bone resorption in osteoblastic cell line CRP 10/30 (13) . Etidronate, alendronate, pamidronate, and olpadronate reportedly prevent apoptosis of murine primary cultured osteoblasts through the activation of p44/p42 MAPK (14) . Pamidronate and zoledronate have recently been shown to enhance the differentiation and boneforming activities of primary cultured human fetal osteoblasts (15) . It has also been reported that pamidronate and clodronate increase the expression of mRNA for osteopontin and RANKL in UMR 106-01 rat osteoblastic osteosarcoma cells (16) . Thus, it is currently speculated that the effects of bisphosphonates on bone metabolism are exerted through not only osteoclasts but also osteoblasts.
PGs are well known to act as autocrine/paracrine modulators of osteoblasts (1, 17) . Among them, PGF 2␣ is recognized to be a potent bone-resorbing agent (17) and stimulates the proliferation and inhibits the differentiation of osteoblasts (17) . In previous studies (18, 19) , we have demonstrated that PGF 2␣ stimulates both phosphoinositide-hydrolyzing phospholipase C (PI-PLC) and phosphatidylcholine-hydrolyzing phospholipase D (PC-PLD), recognized to be two major pathways of physiological protein kinase C (PKC) activation (20, 21) , in osteoblast-like MC3T3-E1 cells. We have also reported that PGF 2␣ activates p44/p42 MAPK through PKC in these cells (22) . In the present study, we investigated whether PGF 2␣ stimulates VEGF synthesis in MC3T3-E1 cells, and if so, the mechanism of VEGF synthesis and the effect of incadronate on the VEGF synthesis. Our results strongly suggest that incadronate enhances the PGF 2␣ -stimulated VEGF synthesis in osteoblasts and that the effect is exerted at the point between PKC and Raf-1. (Osaka, Japan), respectively. Bisindolylmaleimide, 2Ј-amino-3Ј-methoxyflanone (PD98059) and H-Cys-Val-2-naphthylalanine-Met-OH (farnesyltransferase (FTase) inhibitor III) was obtained from Calbiochem-Novabiochem Co. (La Jolla, CA). 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) was obtained from Promega Corp. (Madison, WI). PKC␤I antibodies, phospho-specific p44/p42 MAPK antibodies, p44/p42 MAPK antibodies, phospho-specific MEK1/2 antibodies, MEK1/2 antibodies, and phosphospecific Raf-1 antibodies were purchased from New England BioLabs, Inc. (Beverly, MA). A mouse VEGF ELISA kit and a mouse VEGF mRNA quantitation kit were purchased from R&D Systems, Inc. (Minneapolis, MN). An ECL Western blotting detection system and a QuickPrep total RNA extraction kit were purchased from Amersham Biosciences (Tokyo, Japan). Other materials and chemicals were obtained from commercial sources. PGF 2␣ , cycloheximide, cloprostenol, PGE 2 , PGD 2 , and indomethacin were dissolved in ethanol. PD98059 and U0126 were dissolved in Me 2 SO. FTase inhibitor III was dissolved in acetic acid. The maximum concentration of ethanol, Me 2 SO, or acetic acid was 0.1%, which did not affect the assay for VEGF or the analysis of Western blot.
EXPERIMENTAL PROCEDURES

Materials-PGF
Cell Culture-Cloned osteoblast-like MC3T3-E1 cells derived from newborn mouse calvaria (23) were maintained as previously described (24) . Briefly, the cells were cultured in ␣-minimum essential medium (␣-MEM) containing 10% fetal calf serum (FCS) at 37°C in a humidified atmosphere of 5% CO 2 /95% air. The cells were seeded into 35-mm (5 ϫ 10 4 ) or 90-mm (5 ϫ 10 5 ) diameter dishes in ␣-MEM containing 10% FCS. After 5 days, the medium was exchanged for ␣-MEM containing 0.3% FCS. The cells were used for experiments after 48 h. When indicated, the cells were pretreated with 0.1 M TPA for 24 h, as previously reported (25) .
Assay for VEGF-The cells were stimulated by PGF 2␣ , cloprostenol, PGE 2 , PGD 2 , or NaF in 1 ml of ␣-MEM containing 0.3% FCS for the indicated periods. In some experiments, the pretreatment with cycloheximide or indomethacin was performed for 30 min prior to the stimulation, and the pretreatment with bisindolylmaleimide, PD98059, or U0126 was performed for 60 min. The cells were pretreated with FTase inhibitor III for 4 h. The reaction was terminated by collecting the medium, and VEGF in the medium was measured by using a VEGF ELISA kit. When indicated, the cells were pretreated with incadronate, etidronate, tiludronate, or alendronate for 8 h.
Isolation of RNA and Quantification of mRNA for VEGF-The cultured cells were stimulated by PGF 2␣ or PGE 2 in 1 ml of ␣-MEN containing 0.3% FCS for 2 h. Total RNA was isolated with a QuickPrep total RNA extraction kit. Total RNA (3 g) from each sample was subjected to the quantification of mRNA for VEGF using a mouse VEGF mRNA quantitation kit.
Analysis of PKC␤I, p44/p42 MAPK, MEK1/2, or Raf-1-The cultured cells were stimulated by PGF 2␣ or TPA in 4 ml of ␣-MEM containing 0.3% FCS for the indicated periods. The cells were washed twice with phosphate-buffered saline and then lysed, homogenized, and sonicated in a lysis buffer containing 62.5 mM Tris-HCl, pH 6.8, 2% SDS, 50 mM dithiothreitol, and 10% glycerol. The analysis of PKC␤I translocation to the plasma membrane was performed as previously described (26) . The sample was centrifuged at 15,000 ϫ g for 1 h to generate membrane and cytosolic fractions, and the pellet was resuspended in a lysis buffer. For the analysis of p44/p42 MAPK, MEK1/2, or Raf-1, the cytosolic fraction was collected as a supernatant after centrifugation at 125,000 ϫ g for 10 min at 4°C. SDS-PAGE was performed by Laemmli (27) in 10% polyacrylamide gel. Western blotting analysis was performed as described previously (28) by using PKC␤I antibodies, phospho-specific p44/p42 MAPK antibodies, p44/ p42 MAPK antibodies, phospho-specific MEK1/2 antibodies, MEK1/2 antibodies, or phospho-specific Raf-1 antibodies, with peroxidaselabeled antibodies raised in goat against rabbit IgG being used as second antibodies. Peroxidase activity on the nitrocellulose sheet was visualized on x-ray film by means of the ECL Western blotting detection system. When indicated, the cells were pretreated with incadronate or vehicle for 8 h.
Assay for VEGF in Mouse Plasma in Vivo-C57B mice, obtained from SLC (Sizuoka, Japan), were divided into four groups, a control group (n ϭ 3), a group treated with incadronate (n ϭ 3), a group treated with cloprostenol (n ϭ 3), and a group treated with both compounds (n ϭ 6). Mice were placed in a supine position under anesthesia with an intraperitoneal injection of pentobarbital at a dose of 44 mg/kg. Catheters (Natume Co. Ltd., Tokyo, Japan) were connected to the left jugular vein for the infusion of either incadronate or buffered saline (0.15 M NaCl) and to the right jugular artery for monitoring blood pressure and pulse rate using a pressure transducer (AP601G Nihon Koden, Tokyo, Japan), respectively. Incadronate at a dose of 0.3 mg/kg (0.25 ml) was intravenously injected as a bolus (10% of total volume) and continuously infused for 2 h using an infusion pump via a right jugular vein. Cloprostenol at a dose of 0.2 g per day was administered once a day by subcutaneous injection. In a group of combined treatments, the first administration of cloprostenol was performed at the end of infusion of incadronate, and the daily administration was continued for the indicated periods. Blood samples (0.3 ml) were collected via the jugular vein on sodium citrate (3.15%) under anesthesia with ether at the indicated time point. The plasma concentration of VEGF was measured by using a VEGF ELISA kit. The experiment was performed in accordance with the institutional guidelines.
Determination-The absorbance of ELISA samples was measured at 450 nm with an EL 340 Bio Kinetic Reader (Bio-Tek Instruments, Inc., Winooski, VT). The densitometric analysis was performed using Molecular Analyst/Macintosh (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis-The data were analyzed by analysis of variance followed by the Bonferroni method for multiple comparisons between pairs, and a value of p Ͻ 0.05 was considered significant. All data are presented as the mean Ϯ S.E. of triplicate determinations. Each experiment was repeated three times with similar results. 2␣ stimulated the VEGF synthesis time-dependently up to 48 h in osteoblast-like MC3T3-E1 cells (Fig. 1 ). The VEGF synthesis was significant after 3 h (Fig. 1) . The stimulatory effect of PGF 2␣ on VEGF synthesis was dose-dependent in the range between 1 pM and 10 M (Fig. 2) . The maximum effect of PGF 2␣ was observed at 10 M. Cycloheximide (10 M), an inhibitor of protein synthesis (29) , which by itself had no effect on the VEGF level, markedly inhibited the PGF 2␣ -increased VEGF level (17 Ϯ 2 pg/ml for control; 16 Ϯ 2 pg/ml for 10 M cycloheximide; 1921 Ϯ 153 pg/ml for 10 M PGF 2␣ alone; and 759 Ϯ 62 (p Ͻ 0.05, compared with the value of PGF 2␣ alone) pg/ml for 10 M PGF 2␣ with 10 M cycloheximide pretreatment, as measured during the stimulation for 48 h). PGF 2␣ also increased the level of mRNA for VEGF (Table I) . To clarify whether FP receptor is required for the PGF 2␣ -induced VEGF synthesis or not in MC3T3-E1 cells, we examined the effect of cloprostenol, an FP agonist (30), on the VEGF synthesis. Cloprostenol significantly stimulated the VEGF synthesis (Table II) . PGE 2 is known to be abundantly produced by osteoblasts, including MC3T3-E1 cells, and act as a potent regulator of bone metabolism (17) . Thus, we examined the effect of PGE 2 on the VEGF level in these cells. PGE 2 induced the VEGF synthesis (Table I ) and increased the level of mRNA for VEGF (Table II) . However, the effects were weaker than those of PGF 2␣ . We have previously reported that PGE 1 stimulates VEGF synthesis in MC3T3-E1 cells (11) . In addition, we found that PGD 2 induced VEGF synthesis in these cells (data not shown).
RESULTS
Effects of PGF 2␣ on VEGF Synthesis and the Level of mRNA for VEGF in MC3T3-E1 Cells-PGF
Effect of Indomethacin on the PGF 2␣ -induced VEGF Synthesis in MC3T3-E1 Cells-It is well known that PGs act as autocrine/paracrine modulators of osteoblasts (1, 17) . To clarify whether endogenous PG synthesis is involved in the VEGF synthesis induced by PGF 2␣ , we investigated the effect of indomethacin, a cyclooxygenase inhibitor (31) , on the PGF 2␣ -induced VEGF synthesis in MC3T3-E1 cells. Indomethacin, which alone had little effect on the VEGF synthesis, reduced the VEGF synthesis stimulated by PGF 2␣ in a dose-dependent manner in the range between 3 and 30 M (Fig. 3) .
Effects of PKC Down-regulation or Bisindolylmaleimide on PGF 2␣ -induced VEGF Synthesis in MC3T3-E1 Cells-
We have previously reported that PGF 2␣ activates both PI-PLC and PC-PLD, known as major pathways of PKC activation (20, 21) , in osteoblast-like MC3T3-E1 cells (18, 19) . It has been reported that 24 h of pretreatment of TPA (0.1 M), a PKC-activating phorbol ester (32) , down-regulates PKC in these cells (33) . We also found that the binding capacity of phorbol-12,13-dibutyrate, a PKC-activating phorbol ester (32), in MC3T3-E1 cells treated with TPA for 24 h is reduced to about 30% of the capacity in intact cells (25 
Up-regulation by Incadronate of VEGF Synthesis
PGF 2␣ -stimulated VEGF synthesis in MC3T3-E1 cells, we examined the effect of TPA long term pretreatment on the VEGF. The effect of PGF 2␣ on VEGF synthesis was significantly reduced in the PKC down-regulated cells compared with that in the cells without TPA pretreatment (Table III) . In addition, we examined the effect of bisindolylmaleimide, an inhibitor of PKC (34), on the VEGF synthesis induced by PGF 2␣ in MC3T3-E1 cells. Bisindolylmaleimide, which by itself had little effect on the level of VEGF, significantly suppressed the PGF 2␣ -induced VEGF synthesis in a dose-dependent manner in the range between 1 and 10 M (Fig. 4) .
Effect of PGF 2␣ on the Translocation of PKC␤I to the Plasma Membrane of MC3T3-E1
Cells-It has been reported that, among the PKC family, PKC␣ and PKC␤ mainly exist in osteoblast-like MC3T3-E1 cells, and short term treatment with TPA induces PKC␤ translocation from cytosol to membrane (33) . It is well recognized that the translocation of PKC from cytosol to plasma membrane occurs when PKC is activated (32) . We examined the effect of PGF 2␣ on the PKC␤I translocation to the plasma membrane of these cells. PGF 2␣ elicited the PKC␤I translocation to the plasma membrane (Fig. 5) . The maximum effect of PGF 2␣ was observed at 5 min after the stimulation.
Effects of PD98059, U0126, or FTase Inhibitor III on the PGF 2␣ -induced VEGF Synthesis in MC3T3-E1 Cells-We have previously reported that PGF 2␣ activates p44/p42 MAPK in a PKC-dependent fashion in osteoblast-like MC3T3-E1 cells (22) . To elucidate whether p44/p42 MAPK is involved in the PGF 2␣ -induced VEGF synthesis in these cells, we examined the effect of PD98059, a specific inhibitor of MEK (35) , on the VEGF synthesis induced by PGF 2␣ . PD98059, which alone did not affect the level of VEGF, dose-dependently reduced the PGF 2␣ -induced VEGF synthesis in the range between 0.1 and 50 M (Fig. 6) . The maximum inhibitory effect of PD98059 was observed at 50 M, which caused about 85% reduction of the PGF 2␣ -effect. U0126, another inhibitor of MEK (36) , also suppressed the VEGF synthesis induced by PGF 2␣ (data not shown).
On the other hand, it is well recognized that ligation of many receptors leads to the activation of p44/p42 MAPK through the activation of Ras (37) . GTP-bound Ras interacts with Raf-1, and then Raf-1 activates MEK, the upstream kinase of p44/p42 MAPK (37) . The farnesylation of C-terminal cysteine residue of Ras by FTase is known as the first step of post-translational modification of Ras, resulting in the translocalization of the Ras⅐Raf-1 complex to the membrane, an important process of Raf-1 activation (37, 38) . To investigate whether Ras is involved in the VEGF synthesis induced by PGF 2␣ in MC3T3-E1 cells, we examined the effect of FTase inhibitor III (39) on the VEGF synthesis. FTase inhibitor III, which by itself had little effect on VEGF synthesis, did not affect the VEGF synthesis stimulated by PGF 2␣ (Table IV) .
Effects of Incadronate on the PGF 2␣ -or NaF-induced VEGF Synthesis in MC3T3-E1 Cells-Incadronate, which alone did not affect VEGF synthesis, significantly enhanced the VEGF synthesis induced by PGF 2␣ in a dose-dependent manner in the range between 10 and 50 M (Fig. 7) . The maximum effect of incadronate on the PGF 2␣ -induced VEGF synthesis was observed at 30 M, which caused about 150% enhancement of the PGF 2␣ effect. Other bisphosphonates such as etidronate, tiludronate, or alendronate failed to enhance the PGF 2␣ -induced VEGF synthesis (data not shown). We found that PD98059 reduced the enhancement by incadronate of PGF 2␣ -induced VEGF synthesis (Table V) . FTase inhibitor III failed to affect the enhancement (data not shown).
We have previously reported that heterotrimeric GTP-binding protein is involved in the PGF 2␣ -induced activation of both PI-PLC and PC-PLD in osteoblast-like MC3T3-E1 cells (18, 19) . Thus, we investigated the effect of incadronate on the VEGF synthesis stimulated by NaF, known as a direct activator of heterotrimeric GTP-binding proteins (40) . NaF dose-dependently stimulated VEGF synthesis (data not shown). Incadronate significantly enhanced the NaF-induced VEGF synthesis (Table VI) . 
Effects of Incadronate on the PGF 2␣ -or TPA-induced Phosphorylation of p44/p42 MAPK in MC3T3-E1 Cells-
We next examined the effect of incadronate on the phosphorylation of p44/p42 MAPK induced by PGF 2␣ in MC3T3-E1 cells. Incadronate, which alone did not affect the p44/p42 MAPK phosphorylation, significantly enhanced the PGF 2␣ -induced p44/p42 MAPK phosphorylation (Fig. 8A) . To clarify whether the effect of incadronate is exerted at a point downstream of PKC or not, we examined the effect of incadronate on the TPA-induced phosphorylation of p44/p42 MAPK. We have already found that TPA phosphorylates p44/p42 MAPK in MC3T3-E1 cells (41) . Incadronate markedly enhanced the TPA-induced phosphorylation of p44/p42 MAPK as well as the PGF 2␣ -induced phosphorylation (Fig. 8B) . 2␣ or TPA in MC3T3-E1 Cells-It is well recognized that the activation of p44/p42 MAPK is regulated by MEK1/2, which is regulated by the upstream kinase known as Raf-1 (37). We found that PGF 2␣ and TPA truly induced the MEK1/2 phosphorylation in osteoblast-like MC3T3-E1 cells (Fig. 9) . Thus, we next examined the effect of incadronate on the phosphorylation of MEK1/2 induced by PGF 2␣ in these cells. Incadronate, which by itself hardly affected the phosphorylation, significantly enhanced the phosphorylation of MEK1/2 induced by PGF 2␣ (Fig. 9A) . In addition, TPA-induced phosphorylation of MEK1/2 was markedly amplified by incadronate (Fig. 9B) .
Effects of Incadronate on the Phosphorylation of MEK1/2 and Raf-1 Induced by PGF
We found that PGF 2␣ and TPA induced the phosphorylation of Raf-1 (Fig. 10) . Furthermore, we investigated the effects of incadronate on the phosphorylation of Raf-1 induced by PGF 2␣ or TPA. Incadronate alone had little effect on the phosphorylation of Raf-1 but markedly enhanced the PGF 2␣ -or TPA -induced phosphorylation of Raf-1 (Fig. 10, A and B) .
Effect of Cloprostenol or Incadronate on the Level of VEGF in Vivo-The level of VEGF in mouse plasma was significantly increased after the subcutaneous injection of cloprostenol (Table VII). The effect of cloprostenol was observed from 24 to 72 h (data not shown), and the maximum effect was observed at 48 h. Intravenous administration of incadronate, which by itself had little effect on the VEGF level in mouse plasma, significantly enhanced the cloprostenol-increased VEGF level (Table VII) . DISCUSSION In the present study, we demonstrated that PGF 2␣ induced VEGF synthesis in osteoblast-like MC3T3-E1 cells. We meas- ured VEGF in the conditioned medium in this study. Although the VEGF was secreted from these cells, it is most likely that the changes in long term secretion represent changes in synthesis rather than a specific secretory process. We have previously reported that PGE 1 induces VEGF synthesis in these cells (11) . Herein, we showed that PGE 2 increased the level of mRNA for VEGF and stimulated the synthesis of VEGF. We also found that PGD 2 induced VEGF synthesis in these cells. These findings indicate that several PGs induce the VEGF synthesis in osteoblasts. In the present study, indomethacin (31) reduced the PGF 2␣ -stimulated VEGF synthesis, suggesting that the endogenous PGs are involved in the VEGF synthesis. PGE 2 is known to be abundantly produced by osteoblasts, including MC3T3-E1 cells (17) . We previously reported that PGF 2␣ stimulates the synthesis of PGE 2 in MC3T3-E1 cells (42) . Based on these findings, it is possible that PGE 2 , at least in part, participates in the PGF 2␣ -stimulated VEGF synthesis in these cells.
In our previous studies (18, 19, 22) , we have shown that PGF 2␣ activates PKC through both PI-PLC and PC-PLD via heterotrimeric GTP-binding protein and that p44/p42 MAPK is activated by PGF 2␣ in a PKC-dependent manner. We here showed that bisindolylmaleimide (34) or the down-regulation of PKC suppressed the VEGF synthesis induced by PGF 2␣ . It is well recognized that the translocation of PKC from cytosol to plasma membrane occurs when PKC is activated (32) . We found that PGF 2␣ truly elicited the PKC␤I translocation to the plasma membrane in MC3T3-E1 cells. Therefore, it is probable that PKC␤I is involved in the PGF 2␣ signaling in these cells. In addition, PD98059 and U0126, inhibitors of MEK (35, 36) , inhibited the PGF 2␣ -induced VEGF synthesis, suggesting that the VEGF synthesis is mediated through the activation of p44/p42 MAPK. Therefore, our findings suggest that PGF 2␣ stimulates VEGF synthesis through PKC-and probably PKC␤I-dependent activation of p44/p42 MAPK in osteoblast-like MC3T3-E1 cells. It is well known that MEK1/2 is activated by the upstream kinase, Raf-1 (37) . We previously demonstrated that TPA (32) induces the phosphorylation of p44/p42 MAPK in osteoblast-like MC3T3-E1 cells (41) . Herein, we showed that TPA elicited the phosphorylation of Raf-1 and MEK1/2 in these cells, suggesting that PKC is an upstream regulator of Raf-1-MEK1/2-p44/p42 MAPK cascade. In addition, we here showed that FTase inhibitor III did not affect the PGF 2␣ -induced VEGF synthesis. It is recognized that the farnesylation of C-terminal cysteine residue of Ras by FTase is the first step of the posttranslational modification of Ras, which plays a role in Raf-1 activation (38) . Therefore, it seems unlikely that Ras is involved in the PGF 2␣ -induced VEGF synthesis in MC3T3-E1 cells.
In the present study, incadronate enhanced the PGF 2␣ -induced VEGF synthesis in osteoblast-like MC3T3-E1 cells. We also showed that the VEGF synthesis induced by NaF (40) was augmented by incadronate. We have previously reported that heterotrimeric GTP-binding protein is involved in the PGF 2␣ signaling in these cells (18, 19) . Therefore, it is probable that the enhancement of PGF 2␣ -induced VEGF synthesis by incadronate occurs at a point downstream from the heterotrimeric GTP-binding protein. We next demonstrated that incadronate amplified the phosphorylation of p44/p42 MAPK induced by PGF 2␣ in MC3T3-E1 cells. In addition, PD98059 (35) suppressed the enhancement by incadronate of the PGF 2␣ -induced VEGF synthesis in parallel with the VEGF synthesis stimulated by PGF 2␣ . These findings strongly suggest that incadronate-induced amplification of p44/p42 MAPK activated by PGF 2␣ is tightly coupled to the enhancement of the VEGF synthesis and that the effect is exerted at a point upstream of p44/p42 MAPK. We here presented that incadronate amplified the PGF 2␣ -induced phosphorylation of MEK1/2 as well as that of Raf-1 in these cells, suggesting that the effect is exerted at a point upstream of Raf-1. Furthermore, the phosphorylation of p44/p42 MAPK, MEK1/2, and Raf-1 elicited by TPA (32) was enhanced by incadronate, indicating that the effect is exerted at a point downstream from PKC. We found that FTase inhibitor III did not affect the enhancement by incadronate of VEGF synthesis induced by PGF 2␣ in these cells. Thus, it seems unlikely that the modulation of Ras farnesylation is involved in the enhancement by incadronate of PGF 2␣ -stimulated VEGF synthesis. Taking our results into account, it is most likely that incadronate enhances PGF 2␣ -induced VEGF synthesis, and the effect is exerted at the point between PKC and Raf-1 in osteoblast-like MC3T3-E1 cells. The potential mechanism of incadronate in PGF 2␣ -induced VEGF synthesis in osteoblasts shown here is summarized in Fig. 11 .
VEGF is established as a specific mitogen of vascular endothelial cells (4) . Thus, it is speculated that the synthesis of VEGF by osteoblasts is an important intercellular mediator between the osteoblasts and the vascular endothelial cells. In addition, VEGF is reportedly involved in trabecular bone formation and expansion of the hypertrophic chondrocyte zone in the epiphyseal growth plate of mouse (5) . The expansion of the capillary network providing microvasculature is thought to be essential for the process of bone remodeling. Thus, it is possible that PGF 2␣ -induced VEGF synthesis by osteoblasts through an autocrine/paracrine mechanism promotes the development of vascular endothelial cells in the microenvironment, resulting in the modulation of bone remodeling. Interestingly, it has been reported that incadronate is able to produce intramembranous intramedullary bone formation in vivo. (43) . We herein presented that incadronate truly up-regulated the cloprostenolincreased VEGF level in mouse plasma in vivo. It is well known that bisphosphonates mainly bind bone tissue (12) , whereas cloprostenol is distributed to the whole body and acts through the activation of FP receptor. Therefore, our present findings strongly suggest that incadronate truly affects osteoblasts and enhances the PGF 2␣ -induced VEGF synthesis in vivo. Taking our present findings into account, it is most likely that the enhancement of the VEGF synthesis by incadronate plays an important role in bone metabolism.
Nitrogen-containing bisphosphonates, including incadronate, are recognized to inhibit both farnesyl diphosphate synthase and squalene synthase in osteoclasts (12) . These enzymes play pivotal roles in the mevalonate/cholesterol biosynthetic pathway. It has recently been reported that zoledronate, a nitrogen-containing bisphosphonate, induces differentiation of human fetal osteoblast cells via inhibition of the mevalonate pathway (44) . Another recent report showed that connexin-43, a major gap junction protein, is an essential transducer of the p44/p42 MAPK-activating/anti-apoptotic effects of bisphosphonates in rat osteosarcoma ROS17/2.8 cells or rat calvarial osteoblasts (45) . Herein, we found that other bisphosphonates, etidronate, tiludronate, or alendronate did not enhance the VEGF synthesis induced by PGF 2␣ , suggesting that the enhancement by incadronate is not a common effect of bisphosphonates but a specific effect of incadronate. It has been shown that cycloheptylamino side chain is specific to incadronate (12) . Therefore, it is likely that the unique effect of incadronate is attributed to the structural specificity. Further investigation would be required to clarify the details of the effects of bisphosphonates on bone-forming cells.
In conclusion, our present results strongly suggest that PGF 2␣ stimulates VEGF synthesis through the activation of p44/p42 MAPK in osteoblasts and that incadronate enhances the VEGF synthesis at the point between PKC and Raf-1.
